BellaSeno advances clinical trial for 3D-printed resorbable breast scaffolds in Australia, 30 patients treated

BellaSeno, a German-Australian medical device company, has announced that its clinical trial for 3D-printed resorbable breast scaffolds has reached a new milestone, with 30 women now treated across two studies in Australia. The scaffolds are fabricated from medical-grade polycaprolactone (PCL), a bioresorbable polymer, using an additive manufacturing process. The implants are designed to serve as temporary mechanical support structures that degrade over one to two years, replaced by the patient's own regenerated soft tissue combined with autologous fat grafting. A safety study of 19 patients conducted between 2021 and 2023 reported no scaffold-related complications such as capsular fibrosis, infection, necrosis, or calcification, with a mean volume retention of 83% and high patient satisfaction. A larger pivotal study began in January 2026, with 11 additional patients enrolled and more surgeries scheduled through August.

This development represents a significant step forward in the regenerative medicine segment of additive manufacturing, moving beyond the traditional permanent-implant paradigm. BellaSeno's approach directly addresses the limitations of silicone implants-foreign-body response, capsular contracture, and long-term revision surgery-by leveraging AM's design freedom to create patient-specific, porous scaffolds that guide tissue ingrowth. The clinical data, particularly the absence of scaffold-related complications and high volume retention, positions PCL-based 3D-printed scaffolds as a credible alternative in the breast reconstruction market, which affects hundreds of thousands of women annually post-mastectomy or for congenital conditions. The company is now transitioning from clinical investigation toward commercialization, a phase that will require regulatory approvals beyond the Australian Therapeutic Goods Administration (TGA), including potential FDA 510(k) or CE-MDR pathways, and scaling of manufacturing to meet surgical demand.

From a practical standpoint, BellaSeno must now demonstrate that its scaffold design and manufacturing process can be replicated consistently across multiple surgical sites and patient anatomies, and that the long-term outcomes-beyond the two-year resorption window-remain favorable. The company's next critical hurdle is securing regulatory clearance in larger markets, particularly the US and EU, where the burden of proof for resorbable implants is higher and the competitive landscape includes established players in acellular dermal matrices and synthetic meshes. For surgeons and hospitals evaluating this technology, the key question is whether the 83% volume retention rate holds in a larger, more diverse patient cohort and whether the procedure's complexity and cost can be justified against standard-of-care options. The data so far is promising, but the path to routine clinical use remains measured and evidence-dependent.